ArticleMicrobial cell factories2025
Kinetic modeling of terpenoid production in E. coli: insights into subpopulation emergence and process optimization.
Article in Microbial cell factories, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- High yield strategies for triterpenoid biosynthesis in cell factories.Journal of microbiology (Seoul, Korea) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Escherichia coli is a promising host for terpenoid production, yet kinetic models tailored for such strains are limited—hindering effective bioprocess optimization and control. To address this, we developed a kinetic model of E. coli engineered to produce viridiflorol, aiming to capture the dynamics of key bioprocess variables under both uninduced and induced conditions. To account for growth and metabolism of cells, a simplified central metabolic pathway of E. coli was considered by including acetyl-CoA as the intracellular metabolite due to its role as a common precursor for viridiflorol, acetate, and the TCA cycle. Initial modeling efforts based solely on metabolism failed to reproduce experimental trends, prompting the inclusion of cellular stress caused by IPTG-induced heterologous pathway activation. However, this adjustment alone could not fully explain the observed trends, leading us to hypothesize the emergence of two distinct subpopulations post-induction: (1) stressed, slow-growing producers and (2) dormant non-producers that eventually outgrow producers. After iterative refinements, the model successfully replicated experimental trends with R2 value for glucose, cells, acetate, dissolved oxygen, and viridiflorol being 0.98, 0.88, 0.86, 0.70, and 0.94 respectively. Finally, model simulations were performed for insights which suggested that lowering IPTG concentration can improve viridiflorol production by delaying the emergence of the non-producer population. Guided by the simulations, an optimal IPTG concentration (9.375 µM) for a batch condition was identified, resulting in a titre of 0.14 g/L of viridiflorol. In contrast, a non-optimal IPTG concentration (150 µM) yielded a titre of only 0.03 g/L. Furthermore, experimental validation of the subpopulation hypothesis showed the coexistence of producer and non-producer populations. Taken together, the model captured the bioprocess variable trends, predicted an optimal IPTG concentration for a batch process, and provided insights into the existence of two subpopulations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.